

Correction: Diagnostic performance enhancement of pancreatic cancer using proteomic multimarker panel

Jiyoung Park^{1,2,*}, Yonghwan Choi^{3,14,*}, Junghyun Namkung³, Sung Gon Yi³, Hyunsoo Kim^{1,2}, Jiyoung Yu^{1,2}, Yongkang Kim⁴, Min-Seok Kwon⁴, Wooil Kwon⁵, Do-Youn Oh⁶, Sun-Whe Kim⁵, Seung-Yong Jeong⁵, Wonshik Han⁵, Kyu Eun Lee⁵, Jin Seok Heo⁷, Joon Oh Park⁸, Joo Kyung Park⁹, Song Cheol Kim¹⁰, Chang Moo Kang¹¹, Woo Jin Lee¹², Seungyeoun Lee¹³, Sangjo Han³, Taesung Park⁴, Jin-Young Jang⁵ and Youngsoo Kim^{1,2}

¹ Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, Korea

² Department of Biomedical Engineering, Seoul National University College of Medicine, Seoul, Korea

³ Immunodiagnostics R&D Team, IVD Business Unit 5, SK Telecom, Seoul, Korea

⁴ Department of Statistics, Seoul National University, Seoul, Korea

⁵ Department of Surgery and Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea

⁶ Department of Internal Medicine and Cancer Research Institute, Seoul National University Hospital, Seoul, Korea

⁷ Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

⁸ Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

⁹ Department of Internal Medicine, Seoul National University Hospital Healthcare System Gangnam Center, Seoul, Korea

¹⁰ Department of Surgery, University of Ulsan College of Medicine and Asan Medical Center, Seoul, Korea

¹¹ Department of Surgery, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea

¹² Center for Liver Cancer, National Cancer Center, Seoul, Korea

¹³ Department of Mathematics and Statistics, Sejong University, Seoul, Korea

¹⁴ School of Interdisciplinary Bioscience and Bioengineering, Pohang University of Science and Technology (POSTECH), Pohang, Korea

* The authors have contributed equally to this work

Published: January 12, 2018

Copyright: Park et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

This article has been corrected: Yonghwan Choi is now listed in the 3rd and 14th affiliations and has been added to the equal contribution note.

Original article: Oncotarget. 2017; 8:93117-93130. <https://doi.org/10.18632/oncotarget.21861>